Researchers from the Ontario Drug Policy Research Network (ODPRN) at St.
Institute for Clinical Evaluative SciencesJun 18 2024 Research ers from the Ontario Drug Policy Research Network at St. Michael's Hospital and Public Health Ontario analyzed health data from the Office of the Chief Coroner of Ontario and ICES, and found that there were 210 accidental opioid-related toxicity deaths within shelters between January 2018 to May 2022, with the number of deaths more than tripling during the study period .
People who use Ontario's shelter system are not only facing housing instability, but also have complex healthcare needs and unique barriers to accessing treatment and harm reduction programs. This report underscores the disproportionate impact of the opioid crisis on this population.
Several factors remained consistent with the rest of Ontario, including the rise of multiple substances contributing to death , a greater tendency toward smoking and inhalation of drugs, and fentanyl from the unregulated drug supply being the most common driver of deaths. Urgent need for improved response to crisis "Our report highlights the need for improved and expanded harm reduction approaches, overdose response, as well as staff training and supports within shelters," says co-lead author Tara Gomes, a scientist at the Li Ka Shing Knowledge Institute of St. Michael's Hospital and ICES, and a principal investigator of the ODPRN.
Education Healthcare Hospital Mental Health Overdose Pandemic Public Health Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Surge in fatal opioid overdoses in Ontario shelters, report findsResearchers from the Ontario Drug Policy Research Network (ODPRN) at St.
Read more »
Researchers engineer water-soluble histidine kinase for enhanced antibiotic drug screensA bacterial enzyme called histidine kinase is a promising target for new classes of antibiotics. However, it has been difficult to develop drugs that target this enzyme, because it is a 'hydrophobic' protein that loses its structure once removed from its normal location in the cell membrane.
Read more »
Researchers determine timing is key for type 2 diabetes drug performanceResearchers from the University of Adelaide could be closer to discovering a better way to use metformin, a common type 2 diabetes medication.
Read more »
Researchers create 'chameleon' compound that targets drug-resistant brain cancersIn a new study, Yale researchers describe how a novel chemical compound attacks drug-resistant brain tumors without harming healthy surrounding tissue.
Read more »
Researchers report positive long-term results from study on chronic rhinitis treatmentNeurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced the publication of positive 12-month results from the CLARITY clinical trial in Laryngoscope Investigative Otolaryngology.
Read more »
Researchers report encouraging Phase 1 data for glioblastoma treatmentPreliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham demonstrated that 92% of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months.
Read more »